Haemonetics Corporation
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, inc…
Medical - Instruments & Supplies
US, Boston [HQ]
Insiders
Transactions
Track non-derivative insider transactions.
i = Indirect Ownership
d = Direct Ownership
cs = Common Stock
| Reported Owner(s) | Position Now | Transaction Date | Type | Position Change | Extra | ||
|---|---|---|---|---|---|---|---|
|
$7,373
d
cs
10% Holder
|
11/01/24 |
F
|
161 x $71.48 = $11,508.28 |
Footnotes
#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
#2 This number includes unvested RSUs previously reported as well as 124 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2024.
|
|||
|
$17,807
d
cs
10% Holder
|
09/17/24 |
F
|
238 x $76.54 = $18,216.52 |
Footnotes
#1 Represents shares withheld for tax obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I.
#2 This number includes unvested RSUs previously reported.
|
|||
|
$322,838
d
cs
10% Holder
|
08/29/24 |
J
|
39,704 x $75.56 = $3,000,034.24 |
Footnotes
#1 On August 29, 2024, in an asset substitution transaction, Mr. Simon transferred 39,704 shares of the Issuer's common stock to the Simon Family Irrevocable Trust for the benefit of the reporting person's children, in exchange for cash in the amount of $3,000,034, with the number of shares determined by averaging the high and low sales prices of the Issuer's common stock as reported by the New York Stock Exchange on August 29, 2024. The substitution was made in accordance with the terms of the trust, which has an independent trustee.
#2 This number includes unvested restricted stock units previously reported.
|
|||
|
$18,196
d
cs
10% Holder
|
07/26/24 |
S
|
4,312 x $91.15 = $393,038.80 |
Footnotes
#1 Transaction pursuant to an existing 10b5-1 trading plan dated June 12, 2023 (fully executed as of June 12, 2023).
#2 This number includes unvested restricted stock units previously reported.
|
|||
|
$22,508
d
cs
10% Holder
|
07/25/24 |
F
|
2,798 x $90.58 = $253,442.84 |
Footnotes
#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on July 13, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from July 13, 2021 to July 12, 2024, as certified by the Compensation Committee of the Board of Directors on Jul 24, 2024.
#2 This number includes unvested restricted stock units previously reported.
#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.
|
|||
Get PRO Today
With PRO you will unlock 81 more insider transactions for Haemonetics Corporation
Statistics
Sample Size: 86 Transactions
Sale (S)
40,872 Shares
19.77%
Buy (P)
0 Shares
0.00%
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Abernathy Robert E Director
- Basil Michelle L EVP and General Counsel
- Bryant Diane M Director
- Coyle Michael J Director
- Darecca James EVP, Chief Financial Officer
- Dockendorff Charles J Director
- Galvin Roy President, Global Plasma & BC
- Johnson Lloyd Emerson Director
- Kroll Mark W Director
- Lingamneni Anila EVP, Chief Technology Officer
- Llorens Josep EVP, Global Manufacturing
- Maunsell Farris Maryanne VP, Chief Accounting Officer
- Miller Laurie A. SVP, Human Resources
- Pomeroy Claire Director
- Simon, Christopher President & CEO
- Strong Stewart W President, Global Hospital
- Zane Ellen M Director
Individuals
We summarize earnings call passages, compensations, insider transactions and other information for each individual to get the bigger picture:
- Abernathy Robert E Director
- Basil Michelle L EVP and General Counsel
- Bryant Diane M Director
- Coyle Michael J Director
- Darecca James EVP, Chief Financial Officer
- Dockendorff Charles J Director
- Galvin Roy President, Global Plasma & BC
- Johnson Lloyd Emerson Director
- Kroll Mark W Director
- Lingamneni Anila EVP, Chief Technology Officer
- Llorens Josep EVP, Global Manufacturing
- Maunsell Farris Maryanne VP, Chief Accounting Officer
- Miller Laurie A. SVP, Human Resources
- Pomeroy Claire Director
- Simon, Christopher President & CEO
- Strong Stewart W President, Global Hospital
- Zane Ellen M Director